Progyny (NASDAQ:PGNY) and Solventum (NYSE:SOLV) Head-To-Head Review

Solventum (NYSE:SOLV) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Profitability

This table compares Solventum and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Progyny	4.54%	11.37%	7.73%

Earnings and Valuation

This table compares Solventum and Progyny”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33 billion	1.49	$1.56 billion	$8.87	8.07
Progyny	$1.29 billion	1.16	$58.52 million	$0.65	29.48

Solventum has higher revenue and earnings than Progyny. Solventum is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Solventum has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Progyny has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Solventum and Progyny, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	5	7	0	2.46
Progyny	0	4	9	0	2.69

Solventum presently has a consensus price target of $85.91, suggesting a potential upside of 19.96%. Progyny has a consensus price target of $27.91, suggesting a potential upside of 45.66%. Given Progyny’s stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than Solventum.

Institutional and Insider Ownership

94.9% of Progyny shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Progyny beats Solventum on 8 of the 14 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.